Archive

July 30, 2025

Browsing

Rolls-Royce share price pumped on Tuesday and was hovering near its all-time high of 1,013p. It has increased by 75% this year, surpassing the FTSE 100 Index, which has risen by 11%. 

RR stock price has jumped by over 1,000% in the last five years, while the Footsie has soared by 55% in the same period. This surge has increased its market capitalization to over $113.26 billion, making it the eighth-largest company in the UK. 

High bar before Rolls Royce earnings

The Rolls-Royce share price will be in the spotlight on Thursday after the company publishes its financial results. These earnings come at a time when its stock is at an all-time high and its valuation multiples are in an uptrend.

Rolls-Royce stock now trades at a substantial premium compared to its peers and its history. The company trades at a forward price-to-earnings ratio of 42, much higher than the sector median of 23.

Therefore, these multiples mean that the company needs to publish strong half-year results and upgrade its financial estimates. 

Some analysts are still optimistic that the company has more upside to go in the coming months. For example, in a statement, an analyst at Panmure Liberum said more upside will depend on its profit upgrade. 

The analyst believes that the company’s half-year sales and operating profit will account for a similar share as they did for the full-year in 2024. 

Analysts are upbeat about RR growth

The consensus figures published on its website indicate that analysts anticipate continued growth. They expect that the underlying revenue will be £19.2 billion this year, while the underlying EBIT and profit before tax will jump to £2.87 billion and £2.73 billion, respectively.

These numbers will then continue growing, with its revenue hitting £23.7 billion in 2028 and the EBIT and PBT moving to £4.013 billion and £4.015 billion, respectively. 

Rolls-Royce’s free cash flow is expected to be £4.49 billion in 2028, up from the expected £2.8 billion.

There are indications that Rolls-Royce may publish strong results on Thursday. For one, some of its biggest competitors have recently published strong numbers, pushing their shares much higher. 

For example, GE Vernova stock surged to a record high after saying that its revenue jumped by 11% to $9.1 billion in the second quarter. GEV competes with Rolls-Royce in the power segment

Similarly, GE Aerospace, its biggest competitor, soared to $273, up by 71% from its lowest point this year. Its stock jumped after it published strong results and boosted its forward guidance.

GE’s orders jumped by 27% to $14.2 billion, while its adjusted revenue and operating profits jumped to $10.2 billion and $2.3 billion, respectively. Therefore, since these two companies operate in the same industry, there is a likelihood that it too will release good numbers. 

In its recent trading update, the company maintained its forward operating profit and free cash flow of between £2.7 billion and £2.9 billion. 

Rolls-Royce share price technical analysis

RR stock price chart | Source: TradingView

The daily chart shows that the RR stock price has been in a strong bull run in the past few years. It has crossed the important milestone of 1,000p, as we predicted here and here

On the positive side, the stock is much higher than the 50-day and 100-day moving averages, a sign that bulls are in control. However, on the other hand, the Relative Strength Index (RSI) has formed a descending channel, a sign of bearish diverge pattern.

Therefore, the stock’s outlook is neutral, with the bearish divergence pointing to a pullback to 950p. The alternative scenario is where the stock continues to rally, with the next target being at 1,100p.

The post Rolls-Royce share price sends mixed signals before earnings: buy or sell? appeared first on Invezz

From established players to up-and-coming firms, Canada’s pharmaceutical company landscape is diverse and dynamic.

Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Read on to learn about what’s been driving the share prices of the best-performing Canadian pharma stocks.

1. Cipher Pharmaceuticals (TSX:CPH,OTC:CPHRF)

Year-over-year gain: 48.2 percent
Market cap: C$330.79 million
Share price: C$12.33

Cipher Pharmaceuticals is a specialty pharma company with a diverse portfolio of treatments, including a range of dermatology and acute hospital care products. The company has out-licensed some of its offerings as well. Cipher began trading on the OTCQX Best Market under the symbol CPHRF in early 2024.

In addition to its current portfolio, Cipher has acquired Canadian rights to CF-101, a dermatology treatment for moderate to severe plaque psoriasis is currently expected to undergo Phase III clinical trials. The company is also conducting proof-of-concept studies on DTR-001, a topical treatment for removing tattoos.

In 2024, Cipher announced it had signed a definitive asset purchase agreement with ParaPRO for its US-based Natroba operations and global product rights, and the news caused Cipher’s share price to spike significantly.

During its Q1 results reporting in May 2025, the company announced a US$15 million debt repayment.

2. HLS Therapeutics (TSX:HLS)

Year-over-year gain: 42.03 percent
Market cap: C$154.95 million
Share price: C$4.90

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs. Key commercial products include Vascepa, Clozaril for treatment-resistant schizophrenia and cholesterol-lowering therapies NEXLETOL and NEXLIZET.

Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.

3. Medexus Pharmaceuticals (TSX:MDP,OTC:MEDXF)

Year-over-year gain: 23.25 percent
Market cap: C$92.9 million
Share price: C$2.81

Medexus Pharmaceuticals specializes in bringing drugs to treat rare diseases to North America. The company manages the entire process through its fully integrated operations, from acquiring and developing drugs to marketing and selling them. Some of its key products include treatments for hemophilia B and rheumatoid arthritis, as well as a line of drugs for autoimmune diseases like lupus and allergy treatments.

In November 2024, Medexus Pharmaceuticals announced it had successfully negotiated with the pan-Canadian Pharmaceutical Alliance to make treosulfan, which Medexus commercialized in Canada under the name Trecondyv, available to publicly funded drug programs and patients. Trecondyv is indicated as part of conditioning treatment prior to bone marrow transplants in patients with certain types of blood cancers.

In addition to Canada, Medexus has the exclusive commercialization rights to treosulfan in the US, where it received approval from the US Food and Drug Administration (FDA) in January 2025.

4. Satellos Bioscience (TSXV:MSCL,OTC:MSCLF)

Year-over-year gain: 18 percent
Market cap: C$102.26 million
Share price: C$0.59

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies to regenerate and repair muscle tissue by targeting the specific biological pathways involved. Its lead candidate SAT-3247 targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

The company began enrolment for a multiple-ascending-dose arm of the Phase 1 study for SAT-3247 last November after no drug-related adverse events were reported in the single-ascending-dose group.

In May of this year, Satellos announced results from its Phase 1b trial, reporting SAT-3247 has shown positive safety and pharmacokinetic data and encouraging early functional results, clearing the path for a planned Phase 2 trial.

5. NurExone Biologic (TSXV:NRX,OTC:NRXBF)

Year-over-year gain: 1.41 percent
Market cap: C$44.18 million
Share price: C$0.72

NurExone Biologic is the biopharmaceutical company behind ExoTherapy, a drug delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US Food and Drug Administration (FDA) in October 2023, meaning it has been recognized as a potential treatment for rare medical conditions. The designation makes it eligible for incentives such as market exclusivity and regulatory assistance aimed at accelerating its development and approval.

The company released preclinical results from animal testing evaluating the efficacy of its nano-drug ExoPTEN in restoring lost vision at the end of 2024. In July 2025, preclinical studies indicated that ExoPTEN could improve walking quality in patients with spinal cord injuries.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

After spiraling from crisis to crisis over much of the past seven years, Boeing is stabilizing under CEO Kelly Ortberg’s leadership.

Ortberg, a longtime aerospace executive and an engineer whom the manufacturer plucked from retirement to fix the problem-addled company last year, is set this week to outline significant progress since he took the helm a year ago. Boeing reports quarterly results and gives its outlook on Tuesday.

So far, investors are liking what they’ve been seeing. Shares of the company are up more than 30% so far this year.

Wall Street analysts expect the aircraft manufacturer to halve its second-quarter losses from a year ago when it reports. Ortberg told investors in May that the manufacturer expects to generate cash in the second half of the year. Boeing’s aircraft production has increased, and its airplane deliveries just hit the highest level in 18 months.

It’s a shift for Boeing, whose successive leaders missed targets on aircraft delivery schedules, certifications, financial goals and culture changes that frustrated investors and customers alike, while rival Airbus pulled ahead.

“The general agreement is that the culture is changing after decades of self-inflicted knife wounds,” said Richard Aboulafia, managing director at AeroDynamic Advisory, an aerospace consulting firm.

Analysts expect the company to post its first annual profit since 2018 next year.

“When he got the job, I was not anywhere as near as optimistic as today,” said Douglas Harned, senior aerospace and defense analyst at Bernstein.

Ortberg’s work was already cut out for him, but the challenges multiplied when he arrived.

As the company hemorrhaged cash, Ortberg announced massive cost cuts, including laying off 10% of the company. Its machinists who make the majority of its airplanes went on strike for seven weeks until the company and the workers’ union signed a new labor deal. Ortberg also oversaw a more than $20 billion capital raise last fall, replaced the head of the defense unit and sold off its Jeppesen navigation business.

Ortberg bought a house in the Seattle area, where Boeing makes most of its planes, shortly after taking the job last August, and his presence has been positive, aerospace analysts have said.

“He’s showing up,” Aboulafia said. “You show up, you talk to people.”

Boeing declined to make Ortberg available for an interview.

Boeing’s leaders hoped for a turnaround year in 2024. But five days in, a door-plug blew out of a nearly new Boeing 737 Max 9 as it climbed out of Portland. The almost-catastrophe brought Boeing a production slowdown, renewed Federal Aviation Administration scrutiny and billions in cash burn.

Key bolts were left off the plane before it was delivered to Alaska Airlines. It was the latest in a series of quality problems at Boeing, where other defects have required time-consuming reworking.

Boeing had already been reeling from two deadly Max crashes in 2018 and 2019 that sullied the reputation of America’s largest exporter. The company in May reached an agreement with the Justice Department to avoid prosecution stemming from a battle over a previous criminal conspiracy charge tied to the crashes. Victims’ family members slammed the deal when it was announced.

For years, executives at top Boeing airline customers complained publicly about the manufacturer and its leadership as they grappled with delays. Ryanair CEO Michael O’Leary told investors in May 2022 that management needed a “reboot or boot up the arse.”

Last week, O’Leary had a different tune.

“I continue to believe Kelly Ortberg, [and Boeing Commercial Airplane unit CEO] Stephanie Pope are doing a great job,” he said on an earnings call. “I mean, there is no doubt that the quality of what is being produced, the hulls in Wichita and the aircraft in Seattle has dramatically improved.”

United Airlines CEO Scott Kirby cast doubt over the Boeing 737 Max 10 after the January 2024 door-plug accident, as the carrier prepared not to have that aircraft in its fleet plan. The plane is still not certified, but Kirby has said Boeing has been more predictability on airplane deliveries.

Still, delays for the Max 10, the largest of the Max family, and the yet-to-be certified Max 7, the smallest, are a headache for customers, especially since having too few or too many seats on a flight can determine profitability for airlines.

“They’re working the right problems. The consistency of deliveries is much better,” Southwest Airlines CEO Bob Jordan said in an interview last month. “But there’s no update on the Max 7. We’re assuming we are not flying it in 2026.”

Boeing under Ortberg still has much to fix.

The FAA capped Boeing’s production at 38 Maxes a month, a rate that it has reached. To go beyond that, to a target of 42, Boeing will need the FAA’s blessing.

Ortberg said this year that the company is stabilizing to go beyond that rate. Manufacturers get paid when aircraft are delivered, so higher production is key.

“I would suspect they would be having those discussions very soon,” Harned said. “It’s 47 [a month] that I think is the challenging break.”

He added that Boeing has a lot of inventory on hand to help increase production.

Its defense unit has also suffered. The defense unit encompasses programs like the KC-46 tanker program and Air Force One, which has drawn public ire from President Donald Trump. Trump, frustrated with delays on the two new jets meant to serve the president, turned to a used Qatari Boeing 747 to potentially use as a presidential aircraft, though insiders say that used plane could require months of reoutfitting.

Ortberg replaced the head of that unit last fall.

A strike could also be on the horizon at the defense unit after factory workers “overwhelmingly” rejected a new labor deal, according to their union, the International Association of Machinists and Aerospace Workers Local 837.

“The proposal from Boeing Defense fell short of addressing the priorities and sacrifices of the skilled IAM Union workforce,” the union said Sunday. “Our members are standing together to demand a contract that respects their work and ensures a secure future.”

There is a seven-day cooling off period before a strike would begin, if a new deal isn’t reached.

“They’re not totally out of the woods,” Harned said.

Boeing and Ortberg also need to start thinking about a new jet, some industry members said. Its best-selling 737 first debuted in 1967, and the company was looking at a midsize jetliner before the two crashes sent its attention elsewhere.

“Already there’s been a reversal from ‘read my lips, no new jet.’ I would like to see that accelerate,” Aboulafia said. “He is the guy to make that happen.”

This post appeared first on NBC NEWS

The Senate confirmed President Donald Trump’s pick to lead the Centers for Disease Control and Prevention after his first choice struggled to gain support.

Susan Monarez, a longtime fixture in Washington who has taken on leadership positions in a number of government public health roles, was confirmed by the Senate on Tuesday, crossing yet another position off the lengthy and growing number of nominees awaiting confirmation.

Monarez was confirmed on a 51to 47party line vote.

Across her roughly two-decade career in D.C., she has served as deputy director of the Advanced Research Projects Agency for Health within the Department of Health and Human Services and in roles at the White House, including at the Office of Science and Technology Policy and the National Security Council.

She is the first CDC director to undergo the Senate confirmation process after a new law changed the requirement in 2023. Prior to her confirmation, Monarez had served as the acting director of the CDC since the beginning of this year.

But Monarez, who has a Ph.D. in microbiology and immunology, was not Trump’s first pick to lead the public health agency, which is tasked with protecting Americans from public health threats.

Trump tapped Monarez in March shortly after withdrawing his nomination of Dr. David Weldon, a former House member, after it was clear that he couldn’t get enough votes from Senate Republicans to make it across the finish line.

He lauded Monarez’s credentials, and charged that Americans had ‘lost confidence’ in the CDC.

‘Dr. Monarez will work closely with our GREAT Secretary of Health and Human Services, Robert Kennedy Jr,’ he said on social media at the time. ‘Together, they will prioritize Accountability, High Standards, and Disease Prevention to finally address the Chronic Disease Epidemic and, MAKE AMERICA HEALTHY AGAIN!’

But questions also linger on how well Monarez and Health and Human Services Secretary Robert F. Kennedy Jr. might work together.

During her confirmation hearing last month, Senate Democrats grilled Monarez over whether she agreed with Kennedy’s positions on vaccines. Kennedy has long been outspoken about his skepticism regarding vaccines, particularly COVID-19 vaccines.

The CDC has been hit with thousands of staff cuts and resignations and subject to changes in vaccine policy — notably Kennedy’s decision to remove the COVID-19 from the vaccine schedule for pregnant women and healthy children — in the last six months. 

‘I think vaccines save lives. I think that we need to continue to support the promotion of utilization of vaccines,’ Monarez said during her confirmation hearing.

Her confirmation also comes as Kennedy, in his budget request for the HHS, seeks a slash in funding to the CDC of nearly 50%, or from about $9.2 billion to $4.2 billion, for the upcoming fiscal year.

But Kennedy made clear in an X post at the time of her nomination that he supports Monarez to take on the position.

‘I handpicked Susan for this job because she is a longtime champion of MAHA values, and a caring, compassionate and brilliant microbiologist and a tech wizard who will reorient CDC toward public health and gold-standard science,’ he said. ‘I’m so grateful to President Trump for making this appointment.’

And an HHS spokesperson told Fox News Digital, ‘Once Dr. Monarez is confirmed, the Secretary looks forward to working with her to advance common-sense policies that will Make America Healthy Again.’

This post appeared first on FOX NEWS